Renew Biopharma

Biotech / Pharmaceutical

RENEW BIOPHARMA IS CREATING A PIPELINE OF NON-PSYCHOACTIVE CANNABINOIDS THAT ARE 100 PERCENT PURE, CONTAMINANT-FREE, AND AVAILABLE AT THE INDUSTRIAL SCALE NEEDED TO ENABLE THERAPEUTIC BREAKTHROUGHS. Renew is a synthetic biology company that relies on molecular biology and pathway engineering to produce therapeutic cannabinoids in microorganisms — such as microalgae — instead of using agriculturally-grown Cannabis (marijuana) plants. Plants cannot produce many of the most desirable cannabinoids in sufficient quantities and purity for cost-effective industrial pharmaceutical applications. There are over 100 known cannabinoids that the marijuana plant (Cannabis sativa) naturally produces, yet only THC and CBD are commonly available in large quantity. Other non-abundant cannabinoids are produced by the plant only at low levels and, therefore, have not been readily available for therapeutic studies. Renew is poised to unlock a new, multi-billion-dollar pharmaceutical sector based on a proprietary family of pharmacological chemical compounds — cannabinoids — specifically starting with pure forms of CBG (cannabigerol) and CBD (cannabidiol) and later including many novel cannabinoids that have previously shown promise as therapeutics. Renew’s dominant intellectual property is the result of more than a decade of academic and private-sector research for industrial applications. Renew has exclusive access to novel tools for synthetic biology and genetic engineering of microorganisms for the production of natural and novel cannabinoids. With control of more than 110 issued patents, Renew’s IP includes both specific genes in the biosynthesis of cannabinoids and the ability to engineer a synthetic cannabinoid pathway into microorganisms, including microalgae. The cannabinoid pathway has evolved for millions of years in the Cannabis plant, and the best way to express this pathway outside the Cannabis plant is in another plant, such as microalgae, a single-cell liquid plant.